FDA approves faricimab-svoa for the treatment of retinal vein occlusion
October 27th 2023According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.
Regeneron receives FDA approval for aflibercept injection 8mg for treatment of wet AMD, DME, DR
August 19th 2023According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.
BREAKING NEWS: FDA approves lotilaner ophthalmic solution 0.25% for treatment of Demodex blepharitis
July 25th 2023According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% is the first approved therapeutic for Demodex blepharitis, and has demonstrated efficacy across multiple clinical measures of disease.
AI used to advance drug delivery system for glaucoma and other chronic diseases
June 2nd 2023The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.
New FDA blood donor recommendations could ease restrictions on cornea donations from queer men
June 1st 2023The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities—such as transgender women or nonbinary donors—will be impacted.